Velasco-Murillo V

Language: Spanish
References: 34
Page: 381-387
PDF size: 105.17 Kb.

ABSTRACT

A significant increase for cardiovascular disease and breast cancer risks was found in the Women’s Health Initiative study in 2002, for current users of conjugated equine estrogens in habitual dose of 0.625 mg for hormone replacement therapy (HRT) for treating menopausal symptoms. This unexpected finding has caused newly interest in the world to determine if the use of low-dose estrogens or synthetic estrogens can be useful and safer. At present, there is no scientific evidence about the reduction of such risks with the use of low-dose estrogens. Current medical information has showed that HRT is effective to treat climacteric syndrome and to prevent postmenopausal osteoporosis. In addition, HRT reduces significantly the frequency and severity of vaginal bleeding. Currently the Climacteric and Menopause Program at the Instituto Mexicano del Seguro Social only considers the use of conjugated equine estrogens at the standard dose (0.625 mg). The purpose of this paper is to present some results about use of low-dose estrogens and points of view about synthetic estrogens founded in current medical literature. This review aims at contributing to analyze a possible future use of this type of hormone treatment within the institutional program with the goal to give safer options to clinicians to manage women with menopausal symptoms.

REFERENCES

1. 1. Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002;288(3): 321-333.

2. 2. Reed SD, Newton KM, Lacroix AZ. Indications for hormone therapy: the post-Women’s Health Initiative era. Endocrinol Metab Clin North Am 2004; 33(4):691-715.

3. 3. Ancelin ML, Berr C. Hormonal replacement therapy and Alzheimer’s disease. All quiet on the Western front? Psycol Neuropsychiatr Vieil 2003; 1(4):251-257

4. 4. Prelevic GM, Kocjan T, Markou A. Hormone replacement therapy in postmenopausal women. Minerva Endocrinol 2005;30(1):27-36.

5. 5. Schindler AE. Climacteric symptoms and hormones. Gynecol Endocrinol 2006;22(3):151-154.

6. 6. Azoulay C. Menopause in 2004: “hormone replacement therapy” is not what it used to be anymore. Rev Med Interne 2004;25(11):806-815.

7. 7. Lobo RA. The rationale for low-dose hormonal therapy. Endocrine 2004;24(3):217-221.

8. 8. Peeyananjarassi K, Baber R. Effects of low-dose hormone therapy on menopausal symptoms, bone mineral density, endometrium and the cardio-vascular system: a review of randomized clinical trials. Climacteric 2005;8(1):13-23.

9. 9. Yasui T, Uemura H. Takikawa M, Irahara M. Hormone replacement therapy in postmenopausal women. J Med Invest 2003;50(3):136-145.

10. Burger H. Hormone replacement therapy in the post-Women’s Health Initiative era. Report a meeting held in Funchai, Madeira, February 24-25, 2003. Climacteric 2003;6(Suppl 1):11-36.

11. Faber A, Bouvy ML, Loskamp L, Van den Berg PB, Egberts TC, de Jon-van den Berg LT. Dramatic change in prescribing replacement therapy in the Netherlands after publication of the Million Women Study: a follow-up study. Br J Clin Pharmacol 2005;60(6):641-647.

12. Clanget C, Hinke V, Lange S, Fricke R, Botko R, Pfeilschifter J. Patterns of hormone replacement therapy in a population-based cohort of postmeno-pausal German women. Changes after HERS II and WHI. Exp Clin Endocrinol Diabetes 2005; 113(9):529-533.

13. Haimov-Kochman R, Hochner-Celnikier D. Are there second thoughts about the results of the WHI study? Acta Obstet Gynecol Scand 2006;85(4): 387-393.

14. Dirección de Prestaciones Médicas, Unidad de Salud Pública. Coordinación de Salud Repro-ductiva. Lineamiento técnico-médico para el uso de la terapia hormonal de reemplazo en el clima-terio y la menopausia; México: IMSS; 2005.

15. Mattson LA, Sporrong T. Low dose hormone replacement therapy. Minerva Ginecol 2003; 55(3):201.207.

16. Crandall C. Low-dose estrogen therapy for menopausal women: A review of efficacy and safety. J Women Health 2003;12(8):723-747.

17. Ettinger B. Vasomotor symptom relief versus unwanted effects: role of estrogen dosage. Am J Med 2005;118(12 Suppl 2):74-78.

18. Gambacciani M, Ciaponi M, Cappagli B, Monetleone P, Benussi C, Bevilacqua G, et al. Effects of low-dose, continuous combined replacement therapy on sleep in symptomatic postmenopausal women. Maturitas 2005;50(2):91-97.

19. Marx P, Schade G, Wilbourn S, Blank S, Moyer DL, Nett R. Low-dose (0.3 mg) syinthetic conjugated estrogens is effective for managing atrophic vaginitis. Maturitas 2004;47(1):47-54.

20. Tan D Haines CJ, Limpaphayom KK, Holinka CF, Ausmanas MK. Relief of vasomotor symptoms and vaginal atrophy with three doses of conjugated estrogens and medroxyprogesterone acetate in postmenopausal Asian women from 11 countries: The Pan-Asia menopause (PAM) Study. Maturitas 2005;52(1):35-51.

21. Gambacciani M, Spinetti A, Taponeco F, Cappagli B, Piaggesi L, Fioretti P. Longitudinal evaluation of perimenopausal vertebral bone loss: effects of a low-dose oral contraceptive preparation on bone mineral density and metabolism. Obstet Gynecol 1994; 83(3):392-396.

22. Netter AP, Janaud A. A simple and inexpensive treatment of menopause: prophylaxis of postmeno-pausal bone loss. Hum Reprod 1994;9(10):1801-1802.

23. Lindsay R, Gallagher JC, Kleerekoper M, Pickar JH. Bone response to treatment with lower doses of conjugated estrogens with and without medroxyprogesterone acetate in early postmeno-pausal women. Osteoporosis Int 2005;16(4):372-379.

24. Greenwald MW, Gluck OS, Lang E, Rakov V. Oral hormone therapy with 17-beta-estradiol and 17-beta estradiol in combination with norethindrome acetate in the prevention of bone loss in early postmenopausal women: dose-dependent effects. Menopause 2005;12(6):741-748.

25. Barnabei VM, Cochrane BB, Aragaki AK, Nygaard I, Williams RS, McGovern PG et al. Menopausal symptoms and treatment-related effects of estrogen and progestin in the Women’s Health Initiative. Obstet Gynecol 2005;105(5 Pt 1):1063-1073.

26. Simon JA, Liu JH, Speroff L, Shumel BS, Symons JP. Reduced vaginal bleeding in postmenopausal women who receive combined norethindrone acetate and low-dose ethynyl estradiol therapy versus combined conjugate equine estrogens and medroxy-progesterone acetate therapy. Am J Obstet Gynecol 2003;188(1):92-99.

27. Mattsson LA, Skouby SO, Heikkinen J, Vaheri R, Maenpaa J, Timonen U. A low-dose start in hormone replacement therapy provides a beneficial bleeding profile and few side-effects: randomized comparison with a conventional-dose regimen. Climacteric 2004;7(1):59-69.

28. Pickar JH, Yeh IT, Wheeler JE, Cunnane MF, Speroff L. Endometrial effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate: two-year substudy results. Fertil Steril 2003;80(5): 1234-1240.

29. Wakatsuki A, Ikenoue N, Shinohara K, Watanabe K, Fukaya T. Effect of lower dosage of oral conjugated equine estrogens on inflammatory markers and endothelial function in healthy postmenopausal women. Arterioscler Thromb Vasc Biol 2004;24(3):571-576.

30. Wakatsuki A, Okatani Y, Ikenoue N, Shinohara K, Watanabe K, Fukaya T. Effect of lower dose of oral conjugated equine estrogen on size and oxidative susceptibility of low-density lipoprotein particles in postmenopausal women. Circulation 2003;108(7):808-813.

31. Borgfeldt C, Li C, Samsioe G. Low-dose oral combination of 17beta-estradiol and northisterone acetate in postmenopausal women decreases factor VII, fibrinogen, antithrombine and plasminogen activator inhibitor-1. Climateric 2004;7(1):78-85.

32. Wright J. Hormone replacement therapy: an example of McKinley’s theory on the seven stages of medical innovation. J Clin Nur 2005;14(9): 1090-1097.

33. Velasco-Murillo V. Terapia hormonal de reemplazo. Consideraciones sobre los hallazgos de 2002. Rev Med IMSS 2003;41(4):321-327.

34. Velasco-Murillo V. Tratamiento con estrógenos en el climaterio y la posmenopausia después de 2002. ¿Aún puede prescribirse? Rev Med Inst Mex Seguro Soc 2006;44(1):61-69.